The two-part Phase Ib/II study published in Leukemia by Rambaldi et al. (2020) evaluated the maximum tolerated dose (MTD), safety, and efficacy of givinostat monotherapy in patients with JAK2 V617F-positive polycythemia vera (PV).
Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part Phase Ib/II study / Rambaldi, A., Iurlo, A., Vannucchi, A.M., Noble, R., von Bubnoff, N., Guarini, A., Martino, B., Pezzutto, A., Carli, G., De Muro, M., Luciani, S., McMullin, M.F., Cambier, N., Marolleau, J., Mesa, R.A., Tibes, R., Pancrazzi, A., Gesullo, F., Bettica, P., Manzoni, S., et al.. - In: LEUKEMIA. - ISSN 0887-6924. - ELETTRONICO. - 34:(2020), pp. 2234-2237. [10.1038/s41375-020-0735-y]
Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part Phase Ib/II study
Vannucchi, Alessandro M.;Pancrazzi, Alessandro;Gesullo, Francesca;
2020
Abstract
The two-part Phase Ib/II study published in Leukemia by Rambaldi et al. (2020) evaluated the maximum tolerated dose (MTD), safety, and efficacy of givinostat monotherapy in patients with JAK2 V617F-positive polycythemia vera (PV).
| File | Dimensione | Formato | |
|---|---|---|---|
|
41375_2020_Article_735_safety.pdf
accesso aperto
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Open Access
Dimensione
480.45 kB
Formato
Adobe PDF
|
480.45 kB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
